CRISPR Edited Organoids for Studying Fatty Liver Disease
May 30, 2023 | Terry Sharrer
“Despite being an earlier disease stage, there’s relatively little focus on developing NAFLD treatments compared to NASH therapies, largely because there are no reliable models for understanding the condition. That may be changing thanks to new organoids, or mini organs, developed by scientists from the Hubrecht Institute in the Netherlands. Grown from human stem cells and edited with CRISPR, the organoids can model NAFLD triggered by diet, genetic predisposition and disorders stemming from single-gene mutations, according to study results published Feb. 23 in Nature Biotechnology. The scientists have already used the models to uncover a potential new treatment target.” MORE
Image Credit: Fiercebiotech.com